Log In
Print
BCIQ
Print
Print this Print this
 

Lonsurf, trifluridine/tipiracil (TAS-102)

  Manage Alerts
Collapse Summary General Information
Company Taiho Pharmaceutical Co. Ltd.
DescriptionOral nucleoside antitumor agent composed of a mixture of trifluorothymidine (FTD) and 5-chloro-6-(2-iminopyrrolidin-1-yl)-methyl-2,4(1H,3H)-pyrimidinedione hydrochloride (TPI)
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationColorectal cancer
Indication DetailsTreat metastatic colorectal cancer (mCRC); Treat unresectable advanced or recurrent colorectal cancer refractory to standard therapies
Regulatory Designation

Japan - Standard Review (Treat metastatic colorectal cancer (mCRC))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today